Tetra Discovery Partners, supported by the NIH Blueprint Neurotherapeutics (BPN) program since the program’s inception, is moving an experimental new drug, that may improve memory, into a Phase 1 safety trial. The compound is a first in class phosphodiesterase 4D negative allosteric modulator. It inhibits an enzyme thought to interfere with long-term memory formation and is designed to treat memory loss in early-to-moderate Alzheimer’s disease patients. Read more about Tetra Discovery Partners. The compound is the first drug funded by the BPN to move into a Phase 1 Clinical Trial.
Wednesday, December 30, 2015